Abstract 2989
Background
Past and recent findings indicate that adverse effects of chemotherapy influence the patients’ quality of life. The aim of this study was to investigate the implicated factors that influenced the perceived symptoms and quality of life in cancer patients during chemotherapy.
Methods
A longitudinal study was conducted in a large hospital in a major city of Northern Greece. A total of 200 cancer patients undergoing chemotherapy in cycle 2 and cycle 3 were participated in the research. Data was collected using Memorial Symptom Assessment Scale (MSAS), Functional Assessment Cancer Therapy (FACT-G) additionally with a questionnaire for the demographic and clinical characteristics. Descriptive and conductive statistical methods were applied.
Results
The vast majority of the participants were middle aged (58.94±9.94 years) men (n = 122, 61%) suffering from lung cancer (n = 98, 48%). Analysis based on the chemotherapy cycle status revealed a significant differences in several factors grouping the patients regarding their chemotherapy cycle status (cycle 2 vs cycle 3). Particularly, feeling nervous level, severity and distress of dizziness and the severity in the way of food tastes [p = 0.014, p = 0.001, p < 0.001, p < 0.001 and p = 0.030, respectively] differed statistically significantly. Moreover, multiple logistic regression analysis revealed that gender (p < 0.001) and physical well-being score (p = 0.005) affected perceived symptoms in MSAS. Furthermore, gender, occupational status, diet, type of cancer and family status influenced the overall quality of life in cycle 2 patients (p = 0.002, p < 0.001, p = 0.002, p < 0.001 and p < 0.001 respectively); however, in cycle 3 patients : gender (p = 0.003), occupational status (p < 0.001), educational status (p < 0.001) and diet (p < 0.001) were referred as the most statistically significant variables that influence the overall quality of life.
Conclusions
In conclusion, we demonstrate that adverse effects of chemotherapy in cancer patients play a critical role for the overall quality of patients’ life. Patients demographic or/ and clinicobiological characteristics seem to influence the appearance of the adverse effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4097 - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Presenter: Stephen V Liu
Session: Poster Display session 3
Resources:
Abstract
1129 - Aspirin and Ticagrelor for the prevention of tumour cell induced platelet aggregation
Presenter: Meera Chauhan
Session: Poster Display session 3
Resources:
Abstract
4514 - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Michele Maio
Session: Poster Display session 3
Resources:
Abstract
5169 - In vitro functional interrogation of viable Circulating Tumor Associated Cells (C-TACs) for evaluating Platin resistance.
Presenter: Stefan Schuster
Session: Poster Display session 3
Resources:
Abstract
5827 - Targeting ARG2 as a novel therapeutic approach for cancer
Presenter: Marcin Grzybowski
Session: Poster Display session 3
Resources:
Abstract
3129 - MPS1 and PLK1 as new therapy targets in TP53 mutated solid tumors
Presenter: Balazs Gyorffy
Session: Poster Display session 3
Resources:
Abstract
2129 - The Tumor Static Exposure (TSE) concept & utility: application to combination treatment of radiation and radiosensitizing agent in tumor xenograft experiments
Presenter: Samer El Bawab
Session: Poster Display session 3
Resources:
Abstract
1814 - General Methodology to Optimize Tumor Treating Fields Delivery Utilizing Numerical Simulations
Presenter: Noa Urman
Session: Poster Display session 3
Resources:
Abstract
3010 - The Australian Exceptional Responders Program: a National collaboration
Presenter: Megan Barnet
Session: Poster Display session 3
Resources:
Abstract
4489 - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies
Presenter: Joaquina Baranda
Session: Poster Display session 3
Resources:
Abstract